Key Highlights
- Shares of Tempus AI climbed approximately 24% following positive Phase 3 results from Merck and Moderna’s cancer vaccine collaboration
- The clinical success enhanced the strategic value of Tempus AI’s pending $1.5 billion acquisition of Personalis, a gene-sequencing provider for Moderna’s oncology initiative
- The company achieved its inaugural quarterly GAAP net profit of $5.6 million in Q2 2026, alongside a 22% revenue increase to $382.5 million
- With more than 26% of the float held by short sellers, the rally triggered significant short covering activity
- Wall Street analysts maintain a Moderate Buy rating on TEM with a consensus price target of $62.15
Shares of Tempus AI experienced a substantial 24% gain on Wednesday, reaching approximately $59.64, following the announcement of positive Phase 3 clinical trial results from Merck and Moderna’s collaborative cancer vaccine program.
The market reaction was immediate and powerful. Tempus AI’s pending acquisition of Personalis for $1.5 billion suddenly gained significant strategic importance. Personalis provides critical gene-sequencing capabilities that support Moderna’s cancer vaccine development efforts. Positive Phase 3 data dramatically increased the perceived value of this transaction.
TEM reached an intraday peak of $59.04 during morning trading before climbing higher. The stock now trades substantially above its 52-week low of $40.77.
This surge extends beyond a single catalyst. Multiple favorable developments have emerged for the company over recent weeks.
On July 30, Tempus AI announced its maiden quarterly GAAP net profit of $5.6 million. This represented a dramatic turnaround from the $42.8 million loss recorded in the comparable period last year.
Total revenue reached $382.5 million, representing a 22% year-over-year expansion. Leadership subsequently elevated full-year 2026 revenue projections to a range between $1.595 billion and $1.605 billion, while forecasting Adjusted EBITDA near $65 million.
Short Interest Amplifies Movement
Over 26% of TEM’s available float remains in short positions. This substantial short interest concentration transforms positive momentum into accelerated gains. As share prices rise, short sellers must purchase shares to exit their positions, creating additional upward pressure.
On August 4, research published in Nature Medicine confirmed TEM’s PRISM2 AI platform as a highly accurate tool for cancer diagnosis and patient outcome prediction. This provided independent scientific validation of the company’s foundational technology.
Just two days later on August 6, Tempus AI revealed a strategic collaboration with CellCarta, establishing Tempus as a commercial laboratory partner within CellCarta’s oncology companion diagnostics ecosystem.
Data licensing revenue has emerged as another growth catalyst. The company disclosed a 36% year-over-year expansion in data licensing agreements with pharmaceutical partners including Merck and Gilead.
Wall Street Perspective
Broader equity markets provided a supportive environment. The S&P 500 advanced 0.4% while the Nasdaq gained 0.1% today, though these moves played a minimal role in TEM’s performance.
Wall Street analysts currently assign TEM a Moderate Buy consensus rating, derived from eight Buy recommendations and seven Hold ratings issued over the previous three months. The mean price target stands at $62.15.
Prior to Wednesday’s rally, TEM stock had already appreciated 8% over the preceding three-month period.
The consensus price target of $62.15 suggests approximately 4% additional upside potential from present trading levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
